YTYoshinori Takeda

Yoshinori Takeda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshinori Takeda has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Yoshihiro Mise

    Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan

    16 shared publications
  • Akio Saiura

    Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan

    15 shared publications
  • Ryuji Yoshioka

    Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan

    13 shared publications
  • Atsushi Takahashi

    Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan

    9 shared publications
  • Yoshihito Kotera

    Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan

    9 shared publications
  • Hirofumi Ichida

    Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan

    8 shared publications

Latest Publications

  • CARG Score Predicts Perioperative Chemotherapy Completion in Pancreatic Cancer: Association of Completion with Overall Survival

    by Naoki Iwanaga, Yoshinori Takeda, Atsushi Takahashi, Haruka Tanaka, Shoichi Irie, Hirofumi Ichida, Ryuji Yoshioka, Yoshihiro Mise, Yoshihito Kotera, Akio Saiura

  • Prognostic impact of histopathological response after preoperative chemotherapy for locally advanced perihilar biliary tract cancer

    by Shuichi Koike, Atsushi Takahashi, Masahiro Fujisawa, Masaru Oba, Yoshinori Takeda, Yuki Fukumura, Yoshihito Kotera, Yoshihiro Mise, Ryuji Yoshioka, Akio Saiura

  • Clinical recurrence patterns in hepatocellular carcinoma: greater consistency with the seed-and-soil hypothesis than with the anatomical/mechanical model of dissemination

    by Yoshinori Takeda, Hiroshi Imamura, Hirofumi Ichida, Atsushi Takahashi, Shoichi Irie, Ryuji Yoshioka, Yoshihiro Mise, Akio Saiura

    Background: Recurrences of hepatocellular carcinoma (HCC) characterized by multiple intrahepatic nodules, macrovascular invasion, or extrahepatic metastases are generally considered non-curative and critically determine postoperative prognosis. Although such recurrences are commonly regarded as metastatic events, whether their dissemination primarily follows vascular anatomy or reflects biological compatibility between tumor cells and organ microenvironments remains unclear. We therefore evaluated whether these recurrence patterns are consistent with predictions derived from the anatomical/mechanical hypothesis of tumor dissemination. Methods: We retrospectively analyzed 266 patients who underwent initial liver resection for HCC. We examined (i) associations between subtypes of vascular invasion and subsequent recurrence patterns, (ii) temporal relationships among recurrence types, (iii) hierarchical co-occurrence of these events, and (iv) differences in malignant potential across recurrence types using serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) levels. Results: Portal and hepatic venous invasions occurred largely independently and showed no anatomical specificity in relation to recurrence patterns. Each subtype of vascular invasion was similarly associated with all forms of non-curative recurrence without anatomical specificity. Intrahepatic recurrence did not consistently precede extrahepatic metastasis, and no hierarchical relationship was observed among recurrence types. In contrast, patients with extrahepatic metastases had significantly higher AFP and DCP levels than those with intrahepatic non-curative recurrence. Conclusions: The spatial, temporal, hierarchical, and biological patterns of non-curative recurrence in HCC are more consistent with biologically selective dissemination as conceptualized by the seed-and-soil hypothesis than with the anatomical/mechanical model of dissemination.

  • Long-term outcomes of preoperative chemotherapy for borderline resectable perihilar cholangiocarcinoma

    by Shuichi Koike, Atsushi Takahashi, Shoichi Irie, Yoshinori Takeda, Masaru Oba, Yoshihito Kotera, Yoshihiro Mise, Ryuji Yoshioka, Akio Saiura

  • Reply to Ben Ismail et al.

    by Kenta Aso, Yoshinori Takeda, Akio Saiura

  • Biologically Refined Oncological Resectability for Hepatocellular Carcinoma

    by Kenta Aso, Yoshinori Takeda, Atsushi Takahashi, Shoichi Irie, Yoshihiro Hirata, Hirofumi Ichida, Ryuji Yoshioka, Yoshihito Kotera, Yoshihiro Mise, Akio Saiura

    Background/Purpose: Oncological resectability criteria for hepatocellular carcinoma (HCC) have been proposed to guide multidisciplinary treatment, but their validation remains limited. Incorporating biological factors may improve prognostic stratification and identification of borderline‐resectable HCC. Methods: Patients undergoing initial hepatectomy for HCC (2009–2022) were classified as resectable (R), borderline‐resectable (BR)1, or BR2. Stratification of overall survival (OS) and recurrence‐free survival (RFS) was compared with the BCLC staging system. R‐group patients with alpha‐fetoprotein (AFP) ≥ 400 ng/mL and des‐gamma‐carboxy prothrombin (DCP) ≥ 400 mAU/mL were subclassified as biological‐BR. Results: Among 391 patients (R: 330; BR1: 23; BR2: 38), survival stratification was comparable to the BCLC classification. Twenty‐six R‐group patients were reclassified as biological‐BR, with higher microvascular invasion rates (42.3%) and 5 year OS and 3 year RFS similar to BR1 patients (54.9% vs. 51.3%, p = 0.457; 38.1% vs. 25.0%, p = 0.954). Combining Biological BR with BR1 significantly improved time‐dependent prediction of 6 month recurrence, with an area under the receiver operating characteristic curve (Refined: 0.803; Original: 0.658, p ≤ 0.001, BCLC: 0.608, p ≤ 0.001) and net reclassification improvement (0.220 vs. Original; 0.446 vs. BCLC). Conclusions: Refinement using AFP and DCP identified a biologically aggressive subset within the R group and may improve early recurrence prediction.


  • Open Access

    Pancreatic Head Cancer Masquerading as Distal Cholangiocarcinoma: Diagnostic Challenges, Tumor Characteristics, and Oncologic Outcomes

    by Kenta Aso, Ryuji Yoshioka, Atsushi Takahashi, Shoichi Irie, Yoshinori Takeda, Yoshihiro Hirata, Takaaki Kato, Hirofumi Ichida, Yoshihito Kotera, Yoshihiro Mise, et al.

    Background/Objectives: Differentiating pancreatic head cancer (PHC) from distal cholangiocarcinoma (dCCA) remains clinically challenging and directly influences treatment strategy. This study evaluates the clinicopathologic features and outcomes of patients with PHC who were preoperatively designated as dCCA. Methods: We retrospectively analyzed patients undergoing pancreatoduodenectomy for suspected dCCA or PHC from 2019 to 2023. Patients were stratified by pre- and postoperative diagnoses into three groups: confirmed dCCA (B-B), confirmed PHC (P-P), and dCCA reclassified as PHC (B-P). Clinicopathologic features, perioperative outcomes, and survival were compared. Results: This analysis included 159 patients, B-B = 31, P-P = 115, and B-P = 13. Despite a more advanced stage, a lower R0 rate (p = 0.043), and unplanned portal vein resection confined to B-P (p < 0.001), overall and recurrence-free survival were comparable to P-P (p = 0.363 and 0.183). In multivariable Cox analysis, B-P remained an independent favorable prognostic factor for overall survival (Hazard ratio 0.137, p = 0.020). Conclusions: Approximately one-third of cases initially diagnosed as dCCA were ultimately PHC. These PHC cases mimicking dCCA demonstrated comparable or even superior survival, suggesting a biologically indolent subset. Refinement of diagnostic criteria and integrated clinicopathologic assessment are essential for optimizing preoperative management strategies.

  • Re‐evaluating the diagnostic value of α‐fetoprotein for hepatocellular carcinoma in the direct‐acting antiviral era

    by Yoshinori Takeda, Hiroshi Imamura, Hirofumi Ichida, Ryuji Yoshioka, Yoshihiro Mise, Akio Saiura

    Background: Direct‐acting antivirals (DAAs) achieve sustained virological response (SVR) in most hepatitis C virus (HCV) patients, reducing hepatic inflammation and baseline α‐fetoprotein (AFP). Concurrent shifts toward nonviral hepatocellular carcinoma (HCC) may further improve AFP specificity. This study re‐evaluated the diagnostic performance of AFP and des‐γ‐carboxy prothrombin (DCP). Methods: The authors retrospectively analyzed 388 consecutive patients undergoing curative hepatectomy for HCC. Tumor marker levels measured 4 months postoperatively in recurrence‐free patients at 1 year ( n = 257) served as non‐HCC reference values. Cohorts were stratified by era (pre‐DAA vs. post‐DAA). Diagnostic accuracy was assessed via area under the receiver operating characteristic curve (AUROC). Subgroup analyses used multivariable modeling to test fibrosis and viral status as predictors of baseline (postoperative) AFP. Results: Baseline (postoperative) AFP was lower post‐DAA (3 [2–4] ng/mL) than pre‐DAA (4 [3–7] ng/mL; p < .001). AFP AUROC improved from 0.702 to 0.793 ( p = .014), whereas DCP performance was unchanged. The proportion of HCV‐related HCC declined (30% to 20%; p = .012) and nonviral HCC increased (58% to 66%; p = .093). HCV non‐SVR and advanced fibrosis independently predicted higher baseline (postoperative) AFP. An updated AFP cutoff of 5 ng/mL is supported; the conventional DCP threshold of 40 mAU/mL remains appropriate. Conclusions: In the current era, lower baseline AFP levels are associated with improved diagnostic performance of AFP for HCC. Adoption of a 5 ng/mL AFP cutoff and 40 mAU/mL DCP cutoff appears appropriate for current clinical practice.

  • Open Access

    Pancreatic Cancer after Living-Donor Liver Transplantation: A Case Report of Long-Term Recurrence-Free Survival after Pancreaticoduodenectomy Followed by Adjuvant Chemotherapy

    by Naoki Matsuya, Yoshinori Takeda, Shoichi Irie, Takaaki Kato, Ryuji Yoshioka, Yoshihito Kotera, Yoshihiro Mise, Yuki Fukumura, Akio Saiura

    INTRODUCTION: Malignancies are a major cause of late mortality after liver transplantation (LT), with an incidence significantly higher than that in the general population. Pancreatic cancer (PC) occurring after LT carries a dismal prognosis; however, the feasibility and outcome of surgery and perioperative chemotherapy remain unclear.CASE PRESENTATION: A 73-year-old Japanese woman who had undergone living-donor LT 16 years earlier for hepatitis C virus–related cirrhosis was diagnosed with PC during routine CT surveillance in outpatient follow-up. A 23-mm hypovascular tumor in the pancreatic head was found to abut the portal vein (PV), without nodal or distant metastasis. After initiation of neoadjuvant gemcitabine plus S-1, treatment was discontinued during the first cycle because of S-1–induced enteritis requiring hospitalization and intravenous hydration. After recovery of her general condition, she underwent subtotal stomach-preserving pancreaticoduodenectomy with PV resection and reconstruction. During the operation, the pre-existing hepaticojejunostomy was preserved, and pancreaticojejunostomy was created using the blind end of the preserved afferent Roux limb. She was discharged on POD 25 without major complications. Pathological examination revealed well-differentiated pancreatic ductal adenocarcinoma, ypT2N0M0, Stage IB (UICC 9th edition). She subsequently completed 6 months of adjuvant gemcitabine without severe adverse events. No recurrence has been detected during 3 years of postoperative follow-up.CONCLUSIONS: Early detection and curative-intent surgery followed by adjuvant chemotherapy may contribute to long-term recurrence-free survival in selected LT recipients with localized PC. Careful multidisciplinary management may support safe oncologic treatment in these medically complex patients.